兰瑞肽乙酸盐

兰瑞肽乙酸盐用途

Lanreotide is a a synthetic cyclic octapeptide analogue of somatostatin. Lanreotide inhibits the secretion of growth hormone (GH) by binding to pituitary somatostatin receptors, and may inhibit the release of various other hormones, including thyroid stimulating hormone (TSH) and the gastroenteropancreatic hormones insulin, glucagon and gastrin. This agent also decreases circulating total and free insulin-like growth factor 1 (IGF-I). Lanreotide exhibits a high binding affinity for somatostatin receptor 2 (SSTR-2) and a lesser binding affinity for SSTR-5. However, compared to octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

兰瑞肽乙酸盐名称

[ CAS 号 ]:
127984-74-1

[ 中文名 ]:
兰瑞肽

[ 英文名 ]:
Lanreotide acetate

[中文别名 ]:

兰瑞肽乙酸盐

[英文别名 ]:

Somatuline
Somatuline LP
lanreotide acetate
Somatuline LA
Somatuline Autogel

兰瑞肽乙酸盐物理化学性质

[ 分子式 ]:
C₅₆H₇₃N₁₁O₁₂S₂

[ 分子量 ]:
1156.375

[ 精确质量 ]:
1155.488159

[ 外观性状 ]:
white to off-white

[ 储存条件 ]:
?20°C

兰瑞肽乙酸盐安全信息

[ 符号 ]:

GHS08

[ 信号词 ]:
Warning

[ 危害声明 ]:
H361

[ 警示性声明 ]:
P281

[ 危害码 (欧洲) ]:
Xn

[ 风险声明 (欧洲) ]:
63

[ 安全声明 (欧洲) ]:
36/37

[ 危险品运输编码 ]:
NONH for all modes of transport

兰瑞肽乙酸盐文献

[Drug therapy for acromegaly].

Orv. Hetil. 154(39) , 1527-34, (2013)

Prolonged overproduction of growth hormone, like insulin-like growth factor-1 hypersecretion leads to acromegaly in adults. This is associated with several co-morbidities and increased mortality. Desp...

Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases.

Pituitary 16(3) , 354-62, (2013)

Acromegaly is a rare, chronic, and debilitating disease that results from excessive growth hormone production. Clinically, this disease is associated with enlargement of soft tissue, excessive skeleta...

Control of disease activity and tumor size after introduction of pegvisomant in a lanreotide-resistant acromegalic patient.

Ann. Endocrinol. (Paris.) 74(1) , 49-52, (2013)

We report on a 30-year-old female acromegalic patient treated with the growth hormone (GH) receptor antagonist pegvisomant at a low dose after the failure of long-acting lanreotide, neurosurgery and r...

更多文献